- Home
- CRDL vs GNLX Comparison
CRDL vs GNLX Comparison
Compare CRDL & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- GNLX
- Stock Information
- Founded
- CRDL 2017
- GNLX 2001
- Country
- CRDL Canada
- GNLX United States
- Employees
- CRDL N/A
- GNLX N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- CRDL Health Care
- GNLX Health Care
- Exchange
- CRDL Nasdaq
- GNLX Nasdaq
- Market Cap
- CRDL 105.8M
- GNLX 96.6M
- IPO Year
- CRDL N/A
- GNLX 2023
- Fundamental
- Price
- CRDL $1.37
- GNLX $2.87
- Analyst Decision
- CRDL Strong Buy
- GNLX Strong Buy
- Analyst Count
- CRDL 3
- GNLX 4
- Target Price
- CRDL $9.33
- GNLX $17.75
- AVG Volume (30 Days)
- CRDL 231.5K
- GNLX 151.1K
- Earning Date
- CRDL 08-11-2025
- GNLX 08-13-2025
- Dividend Yield
- CRDL N/A
- GNLX N/A
- EPS Growth
- CRDL N/A
- GNLX N/A
- EPS
- CRDL N/A
- GNLX N/A
- Revenue
- CRDL N/A
- GNLX N/A
- Revenue This Year
- CRDL N/A
- GNLX N/A
- Revenue Next Year
- CRDL N/A
- GNLX N/A
- P/E Ratio
- CRDL N/A
- GNLX N/A
- Revenue Growth
- CRDL N/A
- GNLX N/A
- 52 Week Low
- CRDL $0.77
- GNLX $1.60
- 52 Week High
- CRDL $2.63
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- CRDL 62.48
- GNLX 52.48
- Support Level
- CRDL $1.22
- GNLX $2.75
- Resistance Level
- CRDL $1.50
- GNLX $3.17
- Average True Range (ATR)
- CRDL 0.09
- GNLX 0.25
- MACD
- CRDL -0.01
- GNLX 0.01
- Stochastic Oscillator
- CRDL 89.29
- GNLX 44.74
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.